ACADIA 制药

最新新闻

• 评级变动
  Stifel Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/25
• 评级变动
  Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)
  TipRanks · 2026/9/25
• 评级变动
  BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
  TipRanks · 2026/9/25
• 评级变动
  UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $49
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/10/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。